Perioperative medicine & outcomes
Risk of perioperative cardiorespiratory complications and mortality associated with preoperative glucagon-like peptide-1 receptor agonist use in type 2 diabetes mellitus: a nationwide propensity-score matched study
Main findingResult — go to the resultRelative risk 0.26 95% CI 0.22–0.29Authors' conclusion
Preoperative glucagon-like peptide-1 receptor agonists use was associated with reduced risks of perioperative respiratory complications in people with type 2 diabetes mellitus.
Study context
- Population
- Adults with type 2 diabetes mellitus undergoing surgery in the US, January 1, 2016, to December 31, 2024296,389 matched pairs
- Participants
- 296,389 vs 296,389
- Exposure
- Preoperative GLP-1 RA use vs no GLP-1 RA
- GLP-1 RAn = 296,389
- No GLP-1 RAn = 296,389reference
- Outcome
- Postoperative respiratory complications, including aspiration
- Follow-up
- Within 30 days of surgery
Methodological detailspropensity-score matched, nationwide, TriNetX database
- Propensity-score matched
- Nationwide
- TriNetX database
Main finding
As reported in the abstract
Relative risk
0.26
95% CI 0.22–0.29
P < 0.0001
Events by group
GLP-1 RA vs No GLP-1 RA
RR 0.26 (95% CI 0.22–0.29); P < 0.0001
Observational data: associations, not effects.
Further findings
| Outcome | GLP-1 RA | No GLP-1 RA | RR (95% CI) | P value | |
|---|---|---|---|---|---|
| Pulmonary aspiration | 0.01% | 0.03% | 0.31 (0.20–0.49) | P < 0.0001 | |
| 0.20.5125Relative risk (log scale) |
Respiratory complications by long- vs short-acting GLP-1 RA (subgroup)
- Both long- and short-acting GLP-1 RA use associated with fewer respiratory complications
Original publication
Risk of perioperative cardiorespiratory complications and mortality associated with preoperative glucagon-like peptide-1 receptor agonist use in type 2 diabetes mellitus: a nationwide propensity-score matched study. Br J Anaesth. Published 11 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →